Vistagen Receives FDA Approval to Advance Refisolone Phase 2 Trial for Menopause Hot Flashes

Key Takeaways

• FDA issued ‘Study May Proceed’ letter for Vistagen’s Refisolone IND application targeting menopause hot flashes
• Enables continued Phase 2 clinical development of the intranasal neuroscience treatment
• Represents progress in developing alternatives for vasomotor symptoms affecting millions of menopausal women

---

Vistagen Therapeutics (Nasdaq: VTGN) announced it has received FDA clearance to advance clinical development of Refisolone, marking a significant milestone for the company’s intranasal treatment approach to menopause-related hot flashes.

The FDA’s “Study May Proceed” letter under Vistagen’s Investigational New Drug (IND) application clears the path for further Phase 2 clinical trials evaluating Refisolone’s effectiveness in treating vasomotor symptoms, commonly known as hot flashes, associated with menopause.

Innovative Nose-to-Brain Approach

Vistagen, a late-stage biopharmaceutical company based in South San Francisco, specializes in neuroscience applications using nose-to-brain neurocircuitry technology. This innovative delivery method represents a potential breakthrough in how treatments for neurological and hormonal conditions are administered.

Refisolone’s intranasal delivery system could offer advantages over traditional oral medications, potentially providing faster onset of action and reduced systemic side effects by targeting specific brain circuits involved in temperature regulation.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Patient Need

Vasomotor symptoms affect up to 80% of menopausal women, with many experiencing moderate to severe hot flashes that significantly impact quality of life. Current treatment options include hormone replacement therapy and certain antidepressants, but many women seek alternatives due to contraindications or side effects.

The FDA’s approval to proceed represents validation of Vistagen’s scientific approach and brings the company closer to potentially offering a new treatment option for the estimated 50 million women experiencing menopause in the United States.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Next Steps

With regulatory clearance secured, Vistagen can now initiate patient enrollment and dosing in its Phase 2 clinical program. The company will need to demonstrate both safety and efficacy in reducing the frequency and severity of hot flashes compared to placebo or existing treatments.

Success in Phase 2 trials would position Refisolone for potential Phase 3 development, bringing this novel intranasal therapy closer to market availability for women seeking relief from menopausal symptoms.

---

Frequently Asked Questions

What does this FDA approval mean for patients with menopause symptoms?

The FDA clearance allows Vistagen to continue testing Refisolone in Phase 2 trials, potentially bringing a new intranasal treatment option closer to market for women experiencing hot flashes during menopause.

When will Refisolone be available for patients?

Refisolone is still in Phase 2 clinical development. If trials are successful, the drug would need to complete Phase 3 trials and receive full FDA approval, which typically takes several years.

How does Refisolone’s intranasal delivery compare to existing menopause treatments?

Refisolone’s nose-to-brain delivery system may offer faster action and fewer systemic side effects compared to oral medications, though clinical trials will need to confirm these potential advantages over hormone therapy and other current treatments.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Vabysmo gains EU approval for retinal vein occlusion: what changes next
• MariTide Phase 2 obesity data show up to 20% weight loss at one year